Business Blockbuster - Helpng business to be more visible on Google

Business Daily Media


.

Immuno Cure BioTech acquires Shanghai Teresa Healthcare

Integrating Electroporation Technology & DNA Vaccine Platforms

HONG KONG SAR - Media OutReach - 20 September 2022 - Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in DNA vaccines and immunotherapies, announced today the acquisition of 92.6% of Shanghai Teresa Healthcare, the pioneer of electroporation technology and device in China.

The transaction will be settled in cash and shares. Teresa's shareholders will swap for about 1.5% equity in Immuno Cure while the inventor of Teresa's EP technology, Professor XU Yuhong (徐宇虹), maintains her 7.4% direct equity in Teresa.

Teresa EP device delivers brief electrical pulses to promote efficient penetration of DNA vaccine through cell membrane for the enhancement of gene expression and ultimate immune responses. It is the only such device approved by National Medical Products Administration for the administration of DNA vaccine in China. Such EP technology has been an integral part of Immuno Cure's DNA vaccine delivery strategy from research to clinical stage.

Founded in 2004, Shanghai Teresa is an innovative medical device group focusing in electro immunotherapies and rehabilitation therapies. In 2005, Teresa's electroporation technology was developed to enhance the delivery of DNA medicine, based on the intellectual property generated by Shanghai Jiao Tong University under the National 863 Project. Such EP technology has been proven safe and efficacious after deployment of over 10,000 times in collaboration with more than thirty hospitals for the administration of DNA medicine in numerous human trial subjects.

Immuno Cure has two PD-1-Enhanced DNA vaccines currently in phase 1 clinical trial for prevention of COVID-19 and therapeutic cure of HIV/AIDS.

Dr JIN Xia, CEO of Immuno Cure said, "Immuno Cure has partnered with Teresa over the years in developing customised EP delivery strategy for our PD-1-Enhanced DNA vaccines, which has brought about encouraging results in clinical setting recently. I am pleased with this convergence with Teresa, which will no doubt bring our teams even closer together. Teresa will continue to operate independently while leveraging on Immuno Cure's R&D platform for the development of their next generation non-invasive EP technology for intradermal delivery strategy. Immuno Cure is committed to support the continual growth and success of Teresa."

Ms. CHEN Liye, CEO of Teresa said, "Founded on our long term collaboration, Teresa is excited to become a member of Immuno Cure Group. This move will not only provide us with a much closer R&D relationship, which is essential for our technology advancement but also offer us the financial capability to meet future needs. Teresa treasures our collaborations with other players in the field and look forward to continuing our collaborations with new and sustainable EP technology."

Professor CHEN Zhiwei, Director of AIDS Institute at the University of Hong Kong and the Principal Scientific Advisor of Immuno Cure said, "Our research and development work at the AIDS Institute and Immuno Cure has benefitted from Teresa's EP technology and their diligent collaborative effort over the past 12 years. I am pleased to see their relationship developing into an even closer tie. Look forward to the development of the next generation of EP technology for further optimisation of delivery strategy and patient experience."

Dr Percy CHENG, Chairman of Immuno Cure concludes, "This transaction offers Immuno Cure the opportunity to secure Teresa's EP technology for support of not only R&D but also the clinical administration of our PD-1-Enhanced DNA vaccines. We are pleased with Professor XU's decision to remain as our co-investor in Teresa and are optimistic in the future of EP technology in our DNA vaccine development."Hashtag: #ImmunoCureBiotech

The issuer is solely responsible for the content of this announcement.

Immuno Cure BioTech

Immuno Cure BioTech is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of vaccines and immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-Enhanced DNA vaccine and Anti-Δ42PD1 Blocking Antibody technology platforms.

To learn more about Immuno Cure BioTech, please visit

Shanghai Teresa Healthcare

Founded in 2004, Shanghai Teresa is an innovative medical device group based in Shanghai Zhangjiang Hi-Tech Park, focusing in electro immunotherapies and rehabilitation therapies.

To learn more about Shanghai Teresa Healthcare, please visit




News from Asia

EBANX and Eneba strengthen partnership in Latin America with 138% YoY growth in payment volume

With Pix, Nequi, and Mercado Pago among the most used payment methods by Eneba’s customers, the operation now covers eight countries in the regionCURITIBA, BRAZIL – Media OutReach Newswire – 13 No...

L’OCCITANE Celebrates 50 Years Of Provençal Craftsmanship With Holiday 2026 Collection

Featuring a creative collaboration with artist Caroline Romain-Desfossés, the Maison marks its golden milestone with a festive collection inspired by the art of gifting. KUALA LUMPUR, MALAYSIA – ...

Yicura BioMed Advances Dual Capital and Industrial Strategy: Completes First Closing of Series B Financing Led by Gobi Partners

Advancing Core Product ICVAX® for HIV & Immunotherapy Pipeline for CancersHONG KONG SAR – Media OutReach Newswire – 13 November 2026 – Yicura BioMed ("Yicura"), a clinical-stage immunotherapy ...

LOCUS-T and My Starfish Foundation Launch Illustrated Cancer Book to Make Cancer Information More Accessible

SHAH ALAM, MALAYSIA – Media OutReach Newswire – 13 November 2026 – Malaysian digital marketing agency LOCUS-T has joined hands with My Starfish Foundation (MSF) to launch What Do We Do Next? ...

From Message to Mandate: PRISM Summit 2026 Calls on Communicators to Claim Their Seat at the Governance Table

Inaugural Singapore State of PR and Communications Survey unveiled as senior communicators, journalists and board leaders gather at METT SingaporeSINGAPORE – Media OutReach Newswire – 13 November ...

Former Tencent Cloud AI Executive Eric Muqing Li Appointed Co-CEO of Education AI Company Qimingdaren

CHENGDU, CHINA – Media OutReach Newswire – 13 November 2026 – According to a report by Leiphone, Eric Muqing Li, formerly Head of Global Business at Tencent Cloud AI, has recently been appointed C...

Chongqing: Forging New Connections Across Eurasia — Industry Matchmaking Conference of Chongqing Visit by Eurasian Enterprises Held

CHONGQING, CHINA - Media OutReach Newswire - 13 November 2026 - On November 12, the Industry Matchmaking Conference of Chongqing Visit by Eurasian Enterprises was held at Yuzhou Hotel. Around 700 ...

Bora Group 3Q26: Revenue and Net Income Expansion Continues U.S. Manufacturing and Biologics Footprint Complete; Margin Expansion to Follow as Utilization Improves

HONG KONG SAR – Media OutReach Newswire – 13 November 2026 – Bora Pharmaceuticals ("Bora"; TWSE: 6472; OTCQX: BORAY) today announced its financial results and operational highlights for 3Q2026 an...

CALL-E Lets AI Agents in ChatGPT, Muse and OpenClaw Make Real Phone Calls on Their Users' Behalf

Built by AI Rudder, CALL-E asks the user before every call and reports back with proof of what was agreed.SAN FRANCISCO, US – Media OutReach Newswire – 13 November 2026 – AI Rudder, the Singapore-...

11 Boutique Xinjiang Wineries to Debut in Singapore

The launch programme includes a one-day trade exhibition, Master of Wine masterclass and Michelin-starred pairing dinner, highlighting Xinjiang terroir.SINGAPORE - Media OutReach Newswire - 14 Nov...

Why the secrecy around car insurance?

Every year, millions of Australians receive their car insurance renewal and promise themselves they’ll look at it properly later. Then life gets in ...

Australian workers spend almost an hour a day administering email

Research finds email filing, searching and rework consuming an estimated 58 minutes a day and potentially exposing organisations to millionsAustralian...

Customer Service Is Becoming Part of the Small Business Sales and Marketing Engine

For Customer Service Week, 5-9 October, Thryv is urging small businesses to look beyond generating  enquiries and examine what happens after a custome...

Gift Cards as the gateway to agentic payments

Prepaid and stored value gives consumers the trust and control to try AI shopping agents By Blackhawk Network VP Head of ANZ Kieran Nolan For deca...

Why Data Accumulation Without Governance Undermines Sustainability Goals

In July 2026, Group 2 entities, the second cohort of Australian businesses, began their first reporting period under the mandatory climate disclosur...

Permanent $20,000 Instant Asset Write-Off Gives Small Businesses Greater Planning Certainty

The Federal Government’s decision to permanently legislate the $20,000 instant asset write-off will give eligible small businesses greater certainty...